Request Trial
istock-526091807_fangxianuo
fangxianuo / iStockphoto.com
10 November 2017Americas

LSIPR 50 2017: Anthony Atala—Surgeon by day, researcher by night

While most people in the life sciences industry pick one vocation, Anthony Atala is one of the few who has successfully forged two careers in one field. Atala is a practising surgeon and a researcher in the area of regenerative medicine at the Wake Forest Institute for Regenerative Medicine (WFIRM), a US-based institute for translating scientific discovery into clinical therapies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Explaining genetically engineered rodents to a jury—and ultimately beating Amgen
10 July 2026   Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.
Americas
Exelixis opens two-front patent dispute over Cabometyx copies
9 July 2026   Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.
Americas
LSD trade secrets suit over clinical trail info thrown out by judge
2 July 2026   A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.


Editor's picks

What’s at stake in Australia’s biggest pharma patent appeal in years?
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026

Editor's picks

Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026
Biotech
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026
Biotech
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

More features

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies
Explaining genetically engineered rodents to a jury—and ultimately beating Amgen
Exelixis opens two-front patent dispute over Cabometyx copies
Pillsbury nabs ‘veteran’ IP litigator and trial lawyer from Goodwin
Influential Women in IP 2026: Who made the list?
WilmerHale trade secrets expert moves to new firm
China’s medtech shake-up forces rethink on pricing, IP and innovation
LSD trade secrets suit over clinical trail info thrown out by judge